These AI-designed therapeutics aim to improve upon current GLP-1 therapies ... nucleic acid delivery technology, its AI-driven approach has tailored the genetic sequences to leverage specific ...

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies ... nucleic acid delivery technology, its AI-driven approach has tailored the genetic sequences ...

ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely ... with an established nucleic acid delivery technology, its AI-driven approach has tailored ...

In this case, the two patents at issue referred to antibodies that “bind to specific amino ... acid sequences, but a ‘vast’ number of additional antibodies that it has not.” Amgen sold $1. ...

Researchers from the Mayo Clinic described the efficacy of NPA-7, a potential first-in-class multivalent fusion protein comprising a sequence of 22 amino acids of human BNP fused to the Mas receptor ...

FIGURE 1. Amino acid sequence alignment of pLac Gy and Lac1326. Conserved residues are highlighted in yellow. The four highly conserved amino acid sequences found in laccases are marked by a box and ...

If you continue to have this issue please contact [email protected]. Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...